These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 5466970)
21. FDA holds public meeting on nanotechnology. Traynor K Am J Health Syst Pharm; 2006 Nov; 63(22):2175-7. PubMed ID: 17090732 [No Abstract] [Full Text] [Related]
23. International diversification and US regulatory controls in the pharmaceutical industry. Goedde AG Q Rev Econ Bus; 1982; 22(1):101-10. PubMed ID: 10317195 [No Abstract] [Full Text] [Related]
24. The United States Pharmacopeia. Its value to the professions. Heller WM JAMA; 1970 Jul; 213(4):576-9. PubMed ID: 4914287 [No Abstract] [Full Text] [Related]
25. Nonprescription drugs: an overview. Hodes B Int J Health Serv; 1974; 4(1):125-30. PubMed ID: 4829892 [No Abstract] [Full Text] [Related]
26. Making experimental drugs available for AIDS treatment. Krim M AIDS Public Policy J; 1987; 2(2):1-5. PubMed ID: 11650026 [No Abstract] [Full Text] [Related]
27. When names make claims: ethical issues in medical device marketing. Bramstedt KA Ethics Med; 2004; 20(2):47-57. PubMed ID: 15468483 [No Abstract] [Full Text] [Related]
28. The economic wisdom of regulating pharmaceutical "freebies". Fisher SH Duke Law J; 1991 Feb; (1):206-39. PubMed ID: 10114416 [No Abstract] [Full Text] [Related]
29. Are drugs within a class interchangeable? Furberg CD; Herrington DM; Psaty BM Lancet; 1999 Oct; 354(9185):1202-4. PubMed ID: 10513728 [No Abstract] [Full Text] [Related]
30. Standing on your own feet. Apple WS J Am Pharm Assoc; 1974 Jun; 14(6):278-80. PubMed ID: 4840422 [No Abstract] [Full Text] [Related]
31. Despite curbing new drug shortages, shortfall of drugs a persistent problem. Kuehn BM JAMA; 2013 Feb; 309(6):532-3. PubMed ID: 23403656 [No Abstract] [Full Text] [Related]
32. THE PHYSICIAN AND THE FOOD AND DRUG ADMINISTRATION. SADUSK JF JAMA; 1964 Dec; 190():907-9. PubMed ID: 14214493 [No Abstract] [Full Text] [Related]
33. Progress under the Kefauver-Harris Drug Amendments. Rankin WB Pharmakotherapia; 1964; 2(1):215-22. PubMed ID: 5875717 [No Abstract] [Full Text] [Related]
34. Generic equivalence and non-equivalence of drugs. Smith RN Lancet; 1972 Sep; 2(7776):528-30. PubMed ID: 4115582 [No Abstract] [Full Text] [Related]
35. The food and Drug Administration's view of investigational drugs. MEYERS EL SD J Med Pharm; 1963 Jul; 16():40-6. PubMed ID: 13935340 [No Abstract] [Full Text] [Related]
36. US FDA seeks more pharmaceutical industry cash. Zwillich T Lancet; 2007 Feb; 369(9559):357. PubMed ID: 17283497 [No Abstract] [Full Text] [Related]
37. Minimum acceptable requirements for introduction and marketing of drugs. Lasagna L Drugs; 1974; 7(6):409-13. PubMed ID: 4422210 [No Abstract] [Full Text] [Related]
38. ADVERSE DRUG REACTION REPORTING AND THE RELATED ESTABLISHMENT OF A REGISTRY OF TISSUE REACTIONS TO DRUGS. WESTON JK Med Ann Dist Columbia; 1965 Aug; 34():380-2. PubMed ID: 14338452 [No Abstract] [Full Text] [Related]
39. New drugs: the AMA and the FDA. Appel JZ Ann Allergy; 1966 Jul; 24(7):333-6. PubMed ID: 5941864 [No Abstract] [Full Text] [Related]